Japan Blood Products Organization
Quick facts
Phase 3 pipeline
- GB-0998 · Immunology / Rare Disease
GB-0998 is a recombinant human C1-inhibitor that regulates complement and contact system activation to prevent hereditary angioedema attacks. - Placebo of GB-0998
A placebo control arm in a clinical trial for GB-0998, containing no active pharmaceutical ingredient.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Japan Blood Products Organization portfolio CI brief
- Japan Blood Products Organization pipeline updates RSS
Frequently asked questions about Japan Blood Products Organization
What is Japan Blood Products Organization's pipeline?
Japan Blood Products Organization has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include GB-0998, Placebo of GB-0998.
Related
- Sector hub: All tracked pharma companies